$0.40
-0.01 (-2.58%)
Open$0.41
Previous Close$0.41
Day High$0.42
Day Low$0.39
52W High$4.49
52W Low$1.48
Volume—
Avg Volume70.1K
Market Cap94.18M
P/E Ratio—
EPS$-0.37
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+4,934.9% upside
Current
$0.40
$0.40
Target
$20.19
$20.19
$14.44
$20.19 avg
$28.89
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 14.90M | 15.53M | 15.53M |
| Net Income | 2.54M | 3.35M | 2.88M |
| Profit Margin | 17.0% | 21.6% | 18.5% |
| EBITDA | 5.18M | 5.39M | 5.26M |
| Free Cash Flow | 2.62M | 3.23M | 2.70M |
| Rev Growth | -8.5% | -1.6% | +3.5% |
| Debt/Equity | 0.17 | 0.17 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |